This post is from a suggested group
Welcome to our group Muse! A space for us to connect and share with each other. Start by posting your thoughts, sharing media, or creating a poll.
top of page
Writers
Public·1 friend
Groups Activity: Last 30 Days
New Posts
0
New Friends
0
About
Post your short stories, poems, raps, and any literary works.
Lets chat about process, ideas, and improve our craft together.
Info
- Public
Anyone can view this group.
Visible
Shown to site visitors.
April 17, 2024
Created
Created by
Feed
Muse
Public·3 members
bottom of page
Antibody Drug Conjugate Market Set for Robust Growth Amid Rising Targeted Cancer Therapies
Antibody Drug Conjugate Market – Industry Overview
The global Antibody Drug Conjugate (ADC) market has emerged as a pivotal segment within oncology and targeted drug delivery in recent years. With the increasing prevalence of cancer, combined with the need for highly targeted and effective therapies, ADCs offer a potent treatment strategy that merges the specificity of monoclonal antibodies with the powerful effects of cytotoxic drugs. This innovative therapeutic approach enables targeted delivery of anti-cancer agents to cancer cells while minimizing the impact on healthy tissues. The market has witnessed remarkable growth in recent years and is poised to continue its upward trajectory, driven by technological advancements, rising healthcare investments, and expanding clinical trials globally. As per MRFR analysis, the Antibody Drug Conjugate Market Size was estimated at 8.45 (USD Billion) in 2023. The Antibody Drug Conjugate Market Industry is expected to grow from 9.17(USD Billion) in 2024 to 22.5 (USD Billion) by 2035.